Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 29
2008 25
2009 15
2010 12
2011 11
2012 22
2013 22
2014 25
2015 18
2016 18
2017 19
2018 15
2019 12
2020 12
2021 11
2022 7
2023 3
2024 8
2025 11
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Did you mean g vildagliptin (15 results)?
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Matthews DR, et al. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18. Lancet. 2019. PMID: 31542292 Clinical Trial.
In study period 1, patients received either the early combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and vildagliptin 50 mg twice daily, or standard-of-care initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2 …
In study period 1, patients received either the early combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 m …
Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.
Yang X, Zhang X, Sun C, Zhao C, Kong X, Zhao M, Ji L, Li Y. Yang X, et al. Front Endocrinol (Lausanne). 2025 May 6;16:1575087. doi: 10.3389/fendo.2025.1575087. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40395816 Free PMC article. Clinical Trial.
AIM: We aimed to assess the effects of acarbose and vildagliptin on levels of plasma trimethylamine N-oxide (TMAO) and its metabolic precursor in overweight and obese patients with type 2 diabetes mellitus and ascertain the correlation between TMAO and characteristics of d …
AIM: We aimed to assess the effects of acarbose and vildagliptin on levels of plasma trimethylamine N-oxide (TMAO) and its metabolic …
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P, Tsapas A. Bekiari E, et al. Endocrine. 2016 Jun;52(3):458-80. doi: 10.1007/s12020-015-0841-1. Epub 2015 Dec 29. Endocrine. 2016. PMID: 26714458
This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabetes mellitus (T2DM). We searched MEDLINE, COCHRANE, EMBASE and the drug manufacturer's website for randomised controlled trials of vildagl …
This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabet …
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE. Ahrén B, et al. Diabetologia. 2014 Jul;57(7):1304-7. doi: 10.1007/s00125-014-3222-z. Epub 2014 Mar 29. Diabetologia. 2014. PMID: 24682379
In this work we compared RCT and real-life data on the efficacy of the dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin or sulfonylureas when added to metformin. METHODS: Data were pooled from five RCTs examining vildagliptin (n = 2,788) and sulfonylureas (gli …
In this work we compared RCT and real-life data on the efficacy of the dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin or sulf …
Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis.
Ding Y, Liu Y, Qu Y, Lin M, Dong F, Li Y, Cao L, Lin S. Ding Y, et al. Eur Rev Med Pharmacol Sci. 2022 Apr;26(8):2802-2817. doi: 10.26355/eurrev_202204_28611. Eur Rev Med Pharmacol Sci. 2022. PMID: 35503625 Free article.
CONCLUSIONS: Compared with metformin, vildagliptin combined with metformin could significantly reduce FPG, HbA1c and body weight. When the dose of metformin in the combination group of vildagliptin and metformin is 1500mg/d, the results showed significant reduction …
CONCLUSIONS: Compared with metformin, vildagliptin combined with metformin could significantly reduce FPG, HbA1c and body weight. Whe …
The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. Cai L, et al. J Clin Pharm Ther. 2012 Aug;37(4):386-98. doi: 10.1111/j.1365-2710.2011.01323.x. Epub 2011 Dec 22. J Clin Pharm Ther. 2012. PMID: 22191695 Review.
Compared with placebo, treatment with 50 mg/day of vildagliptin caused neutral weight changes, while 100 mg/day of vildagliptin resulted in slight weight gain [0.95 kg (95% CI, 0.73-1.17 kg)]. ...The incidence of hypoglycaemia was low with vildagliptin, and t …
Compared with placebo, treatment with 50 mg/day of vildagliptin caused neutral weight changes, while 100 mg/day of vildagliptin …
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao Q, Kothny W. McInnes G, et al. Diabetes Obes Metab. 2015 Nov;17(11):1085-92. doi: 10.1111/dom.12548. Epub 2015 Sep 10. Diabetes Obes Metab. 2015. PMID: 26250051
Assessments of the individual MACE components and HF events (requiring hospitalization or new onset) were secondary endpoints. The risk ratio (RR) of vildagliptin (50 mg once- and twice-daily combined) versus comparators (placebo and all non-vildagliptin treatments) …
Assessments of the individual MACE components and HF events (requiring hospitalization or new onset) were secondary endpoints. The risk rati …
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Bundhun PK, Janoo G, Teeluck AR, Huang F. Bundhun PK, et al. BMC Pharmacol Toxicol. 2017 Oct 23;18(1):66. doi: 10.1186/s40360-017-0175-0. BMC Pharmacol Toxicol. 2017. PMID: 29058622 Free PMC article.
In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglitazone or rosiglitazone respectively. METHODS: Online databases were searched for studies comparing vildagliptin with pioglitaz …
In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus …
The effects of vildagliptin on glycemic variability in patients with type 2 diabetes on premixed insulin therapy.
Kong D, Shen Z, Jiang L, Xie X, Yan R, Jing T, Hu Y, Ma J. Kong D, et al. Front Endocrinol (Lausanne). 2025 Jun 20;16:1508918. doi: 10.3389/fendo.2025.1508918. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40620795 Free PMC article. Clinical Trial.
This study aimed to investigate the effect of vildagliptin in these patients. METHODS: This real-world study included patients with type 2 diabetes mellitus (T2DM), who were poorly glycemic controlled on premixed insulin therapy and were subsequently added vildagliptin …
This study aimed to investigate the effect of vildagliptin in these patients. METHODS: This real-world study included patients with t …
Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
Dobrecky-Mery I, Sommer A. Dobrecky-Mery I, et al. Coron Artery Dis. 2021 Jan;32(1):4-9. doi: 10.1097/MCA.0000000000000901. Coron Artery Dis. 2021. PMID: 32310854 Clinical Trial.
We hypothesized that among hospitalized acute coronary syndrome (ACS) patients, the addition of vildagliptin to subcutaneous insulin therapy would reduce the risk of hypoglycemic events. ...Patients were divided into two randomized controlled groups: a subcutaneous rapid-a …
We hypothesized that among hospitalized acute coronary syndrome (ACS) patients, the addition of vildagliptin to subcutaneous insulin …
254 results